Cotinga Pharmaceuticals Inc. (COTQF) Stock

About Cotinga Pharmaceuticals Inc.

Cotinga Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for cancer and other medical conditions currently lacking adequate solutions. Its leading therapeutic asset is COTI-2, an oral small molecule formulated to target the p53 tumor suppressor gene. The company is also progressing COTI-219, another oral small molecule compound, specifically engineered to inhibit mutant forms of KRAS without affecting the normal functions of the KRAS gene. In collaboration with St. Vincent's University Hospital, Cotinga is conducting research to evaluate COTI-2 when combined with eribulin for patients suffering from triple-negative metastatic breast cancer. The company, which was previously known as Critical Outcome Technologies Inc., rebranded to Cotinga Pharmaceuticals Inc. in January 2018. Its corporate base is situated in Toronto, Canada.

Cotinga Pharmaceuticals Inc. (COTQF) stock trades at $0.00 with a market capitalization of $2199. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Cotinga Pharmaceuticals Inc. generates a return on equity (ROE) of 100.00% — well above the market average, a sign of a high-quality business, return on capital employed of 112.39%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.cotingapharma.com